RESUMO
OBJECTIVE: Ulcerative colitis (UC) is a lifelong, relapsing-remitting disease. Patients non-responsive to pharmacological treatment may require a colectomy. We estimated pre-colectomy and post-colectomy healthcare resource utilisation (HCRU) and costs in England. DESIGN/METHOD: A retrospective, longitudinal cohort study indexing adult patients with UC undergoing colectomy (2009-2015), using linked Clinical Practice Research Datalink/Hospital Episode Statistics data, was conducted. HCRU, healthcare costs and pharmacological treatments were evaluated during 12 months prior to and including colectomy (baseline) and 24 months post-colectomy (follow-up; F-U), comparing baseline/F-U, emergency/elective colectomy and subtotal/full colectomy using descriptive statistics and paired/unpaired tests. RESULTS: 249 patients from 26 165 identified were analysed including 145 (58%) elective and 184 (74%) full colectomies. Number/cost of general practitioner consultations increased post-colectomy (p<0.001), and then decreased at 13-24 months (p<0.05). From baseline to F-U, the number of outpatient visits, number/cost of hospitalisations and total direct healthcare costs decreased (all p<0.01). Postoperative HCRU was similar between elective and emergency colectomies, except for the costs of colectomy-related hospitalisations and medication, which were lower in the elective group (p<0.05). Postoperative costs were higher for subtotal versus full colectomies (p<0.001). At 1-12 month F-U, 30%, 19% and 5% of patients received aminosalicylates, steroids and immunosuppressants, respectively. CONCLUSION: HCRU/costs increased for primary care in the first year post-colectomy but decreased for secondary care, and varied according to the colectomy type. Ongoing and potentially unnecessary pharmacological therapy was seen in up to 30% of patients. These findings can inform patients and decision-makers of potential benefits and burdens of colectomy in UC.
Assuntos
Colectomia/economia , Colite Ulcerativa/cirurgia , Custos de Cuidados de Saúde/estatística & dados numéricos , Recursos em Saúde/estatística & dados numéricos , Cuidados Pós-Operatórios/economia , Adulto , Idoso , Tomada de Decisão Clínica , Estudos de Coortes , Colite Ulcerativa/tratamento farmacológico , Procedimentos Cirúrgicos Eletivos/economia , Emergências/economia , Inglaterra/epidemiologia , Feminino , Seguimentos , Recursos em Saúde/economia , Hospitalização/economia , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/epidemiologia , Estudos RetrospectivosRESUMO
PURPOSE: The selective cyclin-dependent kinase 4/6 inhibitor palbociclib was approved in Argentina in 2015 for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) or metastatic breast cancer (MBC) based on phase III study results. The Ibrance Real World Insights (IRIS) study aims to evaluate palbociclib in patients with HR-positive/HER2-negative ABC or MBC in the real-world setting in multiple countries globally. Here we report results from patients enrolled in the IRIS study in Argentina. PATIENTS AND METHODS: This retrospective medical chart review study included postmenopausal women with confirmed HR-positive/HER2-negative ABC or MBC who were treated with palbociclib plus letrozole as first-line endocrine-based therapy or with palbociclib plus fulvestrant in women with disease progression after endocrine therapy. Participating physicians reviewed medical records of up to six patients each, collecting demographic and clinical data. Outcomes included progression-free and overall survival rates. RESULTS: Records were extracted for 162 patients in Argentina (palbociclib plus letrozole, n = 105 [65%]; palbociclib plus fulvestrant, n = 57 [35%]). The 6-month progression-free survival rate was 94% for patients treated with palbociclib plus letrozole and 95% for patients treated with palbociclib plus fulvestrant; 85% and 80% of patients treated with palbociclib plus letrozole were progression free at 12 and 18 months, respectively. Six-month survival rates were 98% for palbociclib plus letrozole and 98% for palbociclib plus fulvestrant; 93% and 89% of patients treated with palbociclib plus letrozole were alive at 12 and 18 months, respectively. CONCLUSION: Results from this first real-world evaluation of clinical outcomes in Argentina suggest that palbociclib plus letrozole or fulvestrant delivers favorable effectiveness, as measured by progression-free and overall survival rates.
Assuntos
Neoplasias da Mama/metabolismo , Neoplasias da Mama/terapia , Piperazinas/uso terapêutico , Inibidores de Proteínas Quinases/uso terapêutico , Piridinas/uso terapêutico , Receptores de Estrogênio/metabolismo , Receptores de Progesterona/metabolismo , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Argentina/epidemiologia , Biomarcadores Tumorais , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/patologia , Comorbidade , Feminino , Pesquisas sobre Atenção à Saúde , Humanos , Letrozol/administração & dosagem , Pessoa de Meia-Idade , Metástase Neoplásica , Estadiamento de Neoplasias , Piperazinas/administração & dosagem , Piperazinas/efeitos adversos , Padrões de Prática Médica , Inibidores de Proteínas Quinases/administração & dosagem , Inibidores de Proteínas Quinases/efeitos adversos , Piridinas/administração & dosagem , Piridinas/efeitos adversos , Receptor ErbB-2/metabolismo , Estudos Retrospectivos , Resultado do TratamentoAssuntos
Transtornos Mieloproliferativos/economia , Transtornos Mieloproliferativos/psicologia , Estudos Transversais , Emoções , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Transtornos Mieloproliferativos/diagnóstico , Transtornos Mieloproliferativos/patologia , Inquéritos e Questionários , Reino UnidoRESUMO
PURPOSE: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor approved for use in postmenopausal women with hormone receptor-positive, human epidermal growth factor 2-negative (HR+/HER2-) advanced/metastatic breast cancer (ABC/MBC). Palbociclib has proven benefits in phase III placebo-controlled studies; however, real-world outcome data are lacking. The Ibrance Real World Insights (IRIS) study evaluated palbociclib use in patients with HR+/HER2- ABC/MBC in the real-world setting in the US, Argentina, and Germany. Here we describe results for the US patient subgroup. PATIENTS AND METHODS: IRIS was a retrospective medical chart review study of patients with confirmed HR+/HER2- ABC/MBC who received palbociclib with either an aromatase inhibitor (AI) as initial endocrine-based therapy in postmenopausal women or fulvestrant-based therapy in women with disease progression following endocrine therapy. Physicians extracted data from patient medical records for ≤16 sequential patients each. Outcomes included progression-free and survival rates. RESULTS: Records were extracted for 652 patients: 360 (55.2%) treated with palbociclib + AI and 292 (44.8%) treated with palbociclib + fulvestrant. The 12-month progression-free rate was 84.1% for patients treated with palbociclib + AI and 79.8% for those treated with palbociclib + fulvestrant; 12-month survival rates were 95.1% for palbociclib + AI and 87.9% for palbociclib + fulvestrant. CONCLUSION: In this first real-world assessment of clinical outcomes in US patients with HR+/HER- ABC/MBC, treatment with palbociclib in combination with AI or fulvestrant demonstrated favorable effectiveness in terms of progression-free and survival rates. Ongoing studies are needed to deliver mature clinical outcome data beyond 12/24 months in the real-world setting.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Ósseas/tratamento farmacológico , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias da Mama/tratamento farmacológico , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Padrões de Prática Médica , Adulto , Idoso , Idoso de 80 Anos ou mais , Inibidores da Aromatase/administração & dosagem , Neoplasias Ósseas/secundário , Neoplasias Encefálicas/secundário , Neoplasias da Mama/patologia , Feminino , Fulvestranto/administração & dosagem , Humanos , Neoplasias Hepáticas/secundário , Neoplasias Pulmonares/secundário , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Piperazinas/administração & dosagem , Piridinas/administração & dosagem , Receptores de Estrogênio/metabolismo , Receptores de Progesterona/metabolismo , Resultado do TratamentoRESUMO
Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs) associated with high disease burden, reduced quality of life (QOL), and shortened survival. To assess how MPNs affect patients, we conducted a global MPN Landmark survey. This online survey of patients with MPNs and physicians was conducted in Australia, Canada, Germany, Japan, Italy, and the United Kingdom. The survey measured MPN-related symptoms and the impact of MPNs on QOL and the ability to work as well as disease-management strategies. Overall, 219 physicians and 699 patients (MF, n = 174; PV, n = 223; ET, n = 302) completed the survey; 90% of patients experienced MPN-related symptoms. The most frequent and severe symptom was fatigue. Most patients experienced a reduction in QOL, including those with low symptom burden or low-risk scores. A substantial proportion of patients reported impairment at work and in overall activity. Interestingly, physician feedback and blood counts were the most important indicators of treatment success among patients, with improvements in symptoms and QOL being less important. Regarding disease management, our study revealed a lack of alignment between physician and patient perceptions relating to communication and disease management, with patients often having different treatment goals than physicians. Overall, our study suggested that therapies that reduce symptom burden and improve QOL in patients with MPNs are crucial in minimizing disease impact on patient daily lives. Additionally, our findings showed a need for improved patient-physician communication, standardized monitoring of symptoms, and agreement on treatment goals.
Assuntos
Efeitos Psicossociais da Doença , Transtornos Mieloproliferativos/terapia , Relações Médico-Paciente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Qualidade de VidaRESUMO
OBJECTIVES: This study examined gastroenterologists' motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behaviour, and explored patient attitudes to biosimilars. METHODS: Data were taken from the Adelphi Real World Biosimilars Programme, a real-world, cross-sectional study undertaken in 2015-2016 with German gastroenterologists and patients with ulcerative colitis or Crohn's disease. Gastroenterologists provided data on their prescribing behaviour and attitudes towards biosimilars, and invited the next eight eligible consecutive consulting patients to complete a detailed questionnaire. For analysis, gastroenterologists were split into 'Investigative', 'Conservative', and 'Other' groups. RESULTS: Overall, 25 gastroenterologists and 136 patients participated. Biosimilars accounted for <15% of all biologic therapies and >80% of gastroenterologists would prescribe a bio-originator rather than biosimilar as 1st line therapy if unrestricted. Patients showed some reluctance to accept biosimilars, although of those receiving biosimilars, 79% were satisfied with the current treatment of their condition, and 69% were satisfied with the control of symptoms. Although at least 35% of patients in each analysis group reported no concerns when starting treatment with a bio-originator or biosimilar, 41% of previously biologic-naïve patients prescribed a biosimilar indicated potential side effects and potential long-term problems, and 24% not knowing enough about the drug, as concerns. CONCLUSION: Results demonstrate that there is reluctance from patients to accept biosimilars and the need to further educate patients who are unsure to allow them to be involved in decision making, highlighting the importance of patient and physician communication. There remains a need for further research into non-clinical switching and the long term impact of prescribing biosimilars.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Medicamentos Biossimilares/uso terapêutico , Colite Ulcerativa/tratamento farmacológico , Doença de Crohn/tratamento farmacológico , Gastroenterologistas/psicologia , Satisfação do Paciente , Atitude , Estudos Transversais , Prescrições de Medicamentos , Alemanha , Humanos , Inquéritos e QuestionáriosRESUMO
The application of biocatalysis for the asymmetric reduction of activated C=C is a powerful tool for the manufacture of high-value chemical commodities. The biocatalytic potential of "-ene" reductases from the Old Yellow Enzyme (OYE) family of oxidoreductases is well-known; however, the specificity of these enzymes toward mainly small molecule substrates has highlighted the need to discover "-ene" reductases from different enzymatic classes to broaden industrial applicability. Here, we describe the characterization of a flavin-free double bond reductase from Nicotiana tabacum (NtDBR), which belongs to the leukotriene B4 dehydrogenase (LTD) subfamily of the zinc-independent, medium chain dehydrogenase/reductase superfamily of enzymes. Using steady-state kinetics and biotransformation reactions, we have demonstrated the regio- and stereospecificity of NtDBR against a variety of α,ß-unsaturated activated alkenes. In addition to catalyzing the reduction of typical LTD substrates and several classical OYE-like substrates, NtDBR also exhibited complementary activity by reducing non-OYE substrates (i.e., reducing the exocyclic C=C double bond of (R)-pulegone) and in some cases showing an opposite stereopreference in comparison with the OYE family member pentaerythritol tetranitrate (PETN) reductase. This serves to augment classical OYE "-ene" reductase activity and, coupled with its aerobic stability, emphasizes the potential industrial value of NtDBR. Furthermore, we also report the X-ray crystal structures of the holo-, binary NADP(H)-bound, and ternary [NADP+ and 4-hydroxy-3-methoxycinnamaldehyde (9a)-bound] NtDBR complexes. These will underpin structure-driven site-saturated mutagenesis studies aimed at enhancing the reactivity, stereochemistry, and specificity of this enzyme.
RESUMO
Several structure-guided optimisation strategies were explored in order to improve the hERG selectivity profile of cathepsin K inhibitor 1, whilst maintaining its otherwise excellent in vitro and in vivo profile. Ultimately, attenuation of clogP and pK(a) properties proved a successful approach and led to the discovery of a potent analogue 23, which, in addition to the desired selectivity over hERG (>1000-fold), displayed a highly attractive overall profile.
Assuntos
Catepsina K/antagonistas & inibidores , Canais de Potássio Éter-A-Go-Go/efeitos dos fármacos , Nitrilas/síntese química , Nitrilas/farmacologia , Bloqueadores dos Canais de Potássio/síntese química , Bloqueadores dos Canais de Potássio/farmacologia , Pirimidinas/síntese química , Pirimidinas/farmacologia , Desenho de Fármacos , Descoberta de Drogas , Indicadores e Reagentes , Modelos Moleculares , Curva ROC , Relação Estrutura-Atividade , Torsades de Pointes/tratamento farmacológicoRESUMO
Morphing structural features of HTS-derived chemotypes led to the discovery of novel 2-cyano-pyrimidine inhibitors of cathepsin K with good pharmacokinetic profiles, for example, compound 20 showed high catK potency (IC(50)=4nM), >580-fold selectivity over catL and catB, and oral bioavailability in the rat of 52%.
Assuntos
Catepsina K/antagonistas & inibidores , Inibidores de Cisteína Proteinase/química , Pirimidinas/química , Administração Oral , Animais , Sítios de Ligação , Catepsina K/metabolismo , Linhagem Celular , Cristalografia por Raios X , Inibidores de Cisteína Proteinase/síntese química , Inibidores de Cisteína Proteinase/farmacocinética , Desenho de Fármacos , Ensaios de Triagem em Larga Escala , Humanos , Pirimidinas/síntese química , Pirimidinas/farmacocinética , Ratos , Ratos Sprague-Dawley , Relação Estrutura-AtividadeRESUMO
What is the point of teaching the history of medicine? Many historians and clinicians find it regrettable that some medical students today will graduate knowing almost nothing of such "greats" of the past as Hippocrates, Galen, Vesalius, Harvey, Lister, and Pasteur. But does this really matter? After all, traditional history of medicine curricula tended to distort medicine's past, omitting the countless errors, wrong turns, fads, blunders, and abuses, in order to tell the sanitized stories of a few scientific superheroes. Modern scholarship has seriously challenged most of these heroic dramas; few of our heroes were as farsighted, noble, or obviously correct as once thought. Joseph Lister, for example, turns out to have had filthy wards, whereas William Harvey was devoted to the Aristotelianism he was long said to have overthrown [1]. But as the history of medicine has become less romanticized, it has also become much more relevant, for it promises to impart useful lessons in the vital importance of scientific scepticism.
Assuntos
História da Medicina , Erros Médicos/história , Pesquisa Biomédica/história , Educação Médica , História do Século XVIII , História do Século XIX , História do Século XXRESUMO
OBJECTIVE: To examine associations between calcium intake in the diet, lifestyle factors, and forearm bone mineral density (BMD) in order to identify population subgroups for targeting by screening programs. METHODS: A questionnaire was sent to a random sample of 15% of the inhabitants aged 20-79 years from 2 Swedish municipalities, and the subsample from one of the municipalities was invited to measurement of BMD. The survey response rate was 74% (n = 1,112/1,510) and participation in BMD measurements was 68% (n = 448/659). RESULTS: Only a tendency ( p = .085) toward direct association between calcium intake and forearm BMD was found, and the best multiple regression model was retained to explain BMD excluded calcium intake. Low calcium intake was, instead, in complementary analyses, found to be correlated with the factors old age, female sex, and urban residence in the best multiple regression model. CONCLUSIONS: Population subgroups whose calcium intake is in a range that justifies preventive action could be identified. Screening programs staffed by public health nurses can thereby be informed regarding the subgroups of the population that are at the highest risk of insufficient calcium intake.
Assuntos
Cálcio da Dieta/administração & dosagem , Deficiências Nutricionais/epidemiologia , Ingestão de Energia , Osteoporose/etiologia , Absorciometria de Fóton , Adulto , Distribuição por Idade , Idoso , Densidade Óssea , Estudos Transversais , Deficiências Nutricionais/complicações , Deficiências Nutricionais/diagnóstico , Deficiências Nutricionais/prevenção & controle , Feminino , Antebraço/diagnóstico por imagem , Humanos , Modelos Lineares , Masculino , Programas de Rastreamento , Pessoa de Meia-Idade , Inquéritos Nutricionais , Osteoporose/diagnóstico , Osteoporose/epidemiologia , Osteoporose/prevenção & controle , Prevalência , Cintilografia , Características de Residência , Fatores de Risco , Distribuição por Sexo , Inquéritos e Questionários , Suécia/epidemiologiaRESUMO
The effects of feeding chemically treated dietary supplements (CTDS) containing sunflower oil and dl-alpha-tocopheryl acetate (TA) on alpha-tocopherol content and fatty acid profile in edible tissues of lambs were estimated. Compared with lambs fed control diet (CD), lambs fed CD plus 250 IU of either TA or CTDS increased serum alpha-tocopherol. The CTDS-fed lambs further increased serum alpha-tocopherol by 29% over those fed CD plus 250 IU of TA. Lambs supplemented with TA or CTDS increased alpha-tocopherol in muscle and adipose tissues as compared with lambs fed CD. The CTDS-fed lambs had higher levels of alpha-tocopherol in gluteus medius (7.55 vs 6.05 mug/g), psoas major (7.43 vs 6.02 mug/g), and subcutaneous fat (12.6 vs 9.98 mug/g) compared with the TA-fed lambs. Feeding lambs CTDS also substantially increased levels of linoleic acid in the adipose tissues while decreasing the content of palmitic and oleic acids.
Assuntos
Ácido Linoleico/metabolismo , Carne/análise , Óleos de Plantas/administração & dosagem , Ovinos , alfa-Tocoferol/análogos & derivados , alfa-Tocoferol/metabolismo , Tecido Adiposo/química , Animais , Dieta , Suplementos Nutricionais , Ácidos Graxos/análise , Ácido Linoleico/análise , Músculo Esquelético/química , Óleos de Plantas/farmacocinética , Óleo de Girassol , Tocoferóis , alfa-Tocoferol/administração & dosagem , alfa-Tocoferol/análise , alfa-Tocoferol/sangue , alfa-Tocoferol/farmacocinéticaRESUMO
In this study, the phenotype of psoriatic keratinocytes and fibroblasts in reconstructed skin models was compared to those constructed from normal cells. Characterization of this model by immunohistochemistry showed that classical markers of keratinocyte differentiation exhibited similar patterns of distribution in the psoriatic models to those derived from normal cells and generally reflected in vivo observations. Some crucial differences, however, were observed between normal and psoriatic models when pro-inflammatory gene expression and keratinocyte proliferation were investigated. Notably, the chemokine receptor CXCR2 was overexpressed in the psoriatic models, and, moreover, was localized to the granular layer of keratinocytes as seen in psoriasis in vivo. Pro-inflammatory genes (tumor necrosis factor alpha [TNF-alpha], interferon gamma [IFN-gamma], and interleukin 8 [IL-8]) were expressed at high levels in the psoriatic models, but were only minimally expressed in the normal models. Models derived from uninvolved psoriatic skin showed the same gene expression profile as those derived from involved skin along with an increased proliferation rate when compared to normal models. These results suggest that psoriatic individuals possess an inherent predisposition to develop the disease phenotype even in the absence of T cells. This study represents a comprehensive characterization of psoriatic human skin reconstructed in vitro, and demonstrates the potential of this model as a valuable tool in drug discovery.
Assuntos
Queratinócitos/citologia , Técnicas de Cultura de Órgãos/métodos , Psoríase/patologia , Psoríase/fisiopatologia , Adulto , Idoso , Especificidade de Anticorpos , Células Cultivadas , Quimiocina CXCL1 , Quimiocinas CXC/genética , Quimiocinas CXC/imunologia , Feminino , Expressão Gênica/imunologia , Humanos , Imuno-Histoquímica , Peptídeos e Proteínas de Sinalização Intercelular/genética , Peptídeos e Proteínas de Sinalização Intercelular/imunologia , Interferon gama/genética , Interferon gama/imunologia , Interleucina-6/genética , Interleucina-6/imunologia , Interleucina-8/genética , Interleucina-8/imunologia , Queratinócitos/fisiologia , Masculino , Pessoa de Meia-Idade , Fenótipo , Psoríase/imunologia , Receptores de Interleucina-8A/genética , Receptores de Interleucina-8A/imunologia , Receptores de Interleucina-8B/genética , Receptores de Interleucina-8B/imunologia , Fator de Necrose Tumoral alfa/genética , Fator de Necrose Tumoral alfa/imunologiaRESUMO
BACKGROUND: This study tested a breast cancer education intervention for African American women with poor screening histories. Disparities in rates of later-stage disease and death may be related to lower screening rates due to behavioral (e.g., knowledge gap) and structural (e.g., access) barriers. METHODS: 94 African American women (low-income, poor screening histories) were randomly assigned for an educational and on-site screening intervention, or non-intervention status. Primary care sites were used for educational purposes. Three-month post-intervention mammography was assessed. RESULTS: The intervention group had significantly higher screening rates than the non-intervention group. The latter had a knowledge gap, poor screening history, cancer fears, and insurance differences relative to the screened women. Screening was predicted by behavioral, rather than structural factors. CONCLUSIONS: Since low-income African American women face behavioral and structural barriers to breast cancer screening, an educational program that improves knowledge levels and is offered in primary care sites can effectively impact screening.